CoChat
Cited by 161

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Effects of an 11 β ‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome

Feig, P. U., Shah, S., Hermanowski‐Vosatka, A., Plotkin, D., Springer, M. S., Donahue, S., Thach, C., Klein, E. J., Lai, E., Kaufman, K. D. · 2011 · Diabetes, Obesity and Metabolism

Abstract

Aim: We examined the effects of the 11 β ‐hydroxysteroid dehydrogenase type 1 (HSD1) inhibitor, MK‐0916, on the multiple components of the metabolic syndrome (MetS) in patients with type 2 diabetes (T2DM) and MetS. Methods: This was a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled study. Patients with T2DM (mean baseline A1C: 7.3%) and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)‐defined MetS were randomized 1 : 1 : 1 : 1 to 0.5, 2 or 6 mg/day MK‐0916 or placebo. The primary efficacy endpoint was a change from baseline at week 12 in fasting plasma glucose (FPG). Secondary endpoints included glycosylated haemoglobin A 1c (A1C), 2‐h postprandial glucose (2‐h PPG), body weight, waist circumference, blood pressure and lipid profile. Results: Treatment with MK‐0916 had no significant effect relative to placebo on FPG at week 12. Compared to placebo, 6 mg MK‐0916 produced a modest, significant (p = 0.049) reduction in A1C of 0.3% at week 12, but no significant difference was observed in 2‐h PPG. Six milligram MK‐0916 increased LDL‐C relative to placebo by 10.4% (p = 0.041). Treatment with MK‐0916 led to modest dose‐dependent decreases in blood pressure and body weight. Overall, MK‐0916 was generally well tolerated. MK‐0916 produced mechanism‐based activation of the hypothalamic–pituitary–adrenal axis, resulting in mean increases in adrenal androgen levels that remained within the normal range at all doses tested. Conclusions: Inhibition of HSD1 with MK‐0916 was generally well tolerated in patients with T2DM and MetS. Although no significant improvement in FPG was observed with MK‐0916 compared to placebo, modest improvements in A1C, body weight and blood pressure were observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01375.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 161

Metadata

Authors
Feig, P. U., Shah, S., Hermanowski‐Vosatka, A., Plotkin, D., Springer, M. S., Donahue, S., Thach, C., Klein, E. J., Lai, E., & Kaufman, K. D.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-04-20
Volume
13
Issue
6
Pages
498-504
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1965576057
Cited by
161
References
4
FWCI
14.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.